What Is an FDA Warning Letter?
An FDA Warning Letter is a formal regulatory communication indicating the FDA has identified significant violations of regulations it enforces. Warning letters are public documents. Receiving one does not automatically shut down a company — but it is a serious enforcement action that requires timely response and documented corrective action. For patients, a warning letter is a material fact worth understanding before making a financial commitment to any telehealth program.
What the FDA Cited Against NewSelf
The FDA's February 2026 warning letter to NewSelf LLC cited violations in two primary areas:
- Misbranding: NewSelf's compounded GLP-1 website allegedly characterized compounded semaglutide products in ways that misrepresented their regulatory status under FDA definitions — specifically, implying they were equivalent to or the same as brand-name FDA-approved drugs
- False or misleading labeling claims: Marketing representations about the products' efficacy, equivalence to Ozempic/Wegovy, and regulatory standing that the FDA determined were false or misleading under 21 U.S.C. § 352
Key distinction: The FDA warning was directed at the NewSelf platform marketing and labeling content — not at the 503A compounding pharmacies that prepare and dispense the actual medication. The pharmacies were not cited in this specific action.
⚡ Limited Time: Free Overnight Shipping
Understand the FDA context before you enroll. Start your free NewSelf clinical visit with full information.
✓ All dosages same price · ✓ Full refund if declined · ✓ No membership fees
NewSelf's Response
NewSelf disputed the FDA's characterization of its labeling practices and committed to response within the required regulatory window. The company's position was that its website accurately represented the legal status and nature of its compounded products. As of September 2026, the outcome of the formal FDA response has not been publicly confirmed in the FDA warning letter database. Verify current compliance status directly before enrolling.
Context: FDA and Compounded GLP-1 Broadly
The FDA has increased enforcement activity across the compounded GLP-1 telehealth market broadly as semaglutide and tirzepatide drug shortages have begun to resolve. Multiple providers — not only NewSelf's program — have received regulatory communications about labeling and marketing compliance as the compounding authorization basis changes. The end of drug shortage designations affects the legal authority for compounding these specific molecules, making regulatory compliance increasingly important across the category.
Should the Warning Letter Stop You From Using NewSelf?
That is a personal risk tolerance decision. The FDA warning letter alone does not make start a NewSelf GLP-1 plan fraudulent or its medications definitively unsafe. It does add a meaningful regulatory risk factor that peers without warning letters do not carry. If FDA regulatory compliance record is your primary criterion, providers without outstanding warning letters (GobyMeds, Henry Meds) offer lower-risk alternatives. See our NewSelf vs GobyMeds comparison and full GLP-1 market comparison.